| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price |
|---|---|---|---|---|---|---|---|---|
| HLA-A*0201 & B2M & Vaccinia virus (IMYDIINSV) | Biotinylated Human HLA-A*02:01&B2M&Vaccinia virus (IMYDIINSV) Complex Protein (Monomer, MALS verified) |  Human | HEK293 | MALSSDS-PAGE | $125.00 25ug |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Olaptesed Pegol | NOX-A12 | Phase 2 Clinical | Noxxon Pharma | Hematopoietic stem cell transplantation (HSCT); Glioblastoma; Pancreatic Neoplasms; Multiple Myeloma; Colorectal Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| PTX-9908 | PTX-9908 | Phase 2 Clinical | Pertinax Therapeutics | Carcinoma, Hepatocellular | Details |
| Emilimogene sigulactibac | ILP100h | Phase 2 Clinical | Ilya Pharma AB | Diabetic Foot; Wounds and Injuries | Details |
| JVS-100 | JVS-100; SRX-100; ACRX-100; GP-51801; GP51801 | Phase 1 Clinical | Cleveland Clinic | Heart Failure; Ischemia; Surgical Wound; Peripheral Arterial Disease | Details |
| CK-0804 | CK-0804 | Phase 1 Clinical | Cellenkos Inc | Primary Myelofibrosis | Details |
| Dociparstat sodium | ODSH; CX-01; PGX-100; PGX-ODSH-2013-AML-1 | Phase 1 Clinical | Paringenix | Coronavirus Disease 2019 (COVID-19); Pancreatic Neoplasms; Myelodysplastic Syndromes; Protein-Losing Enteropathies; Pulmonary Disease, Chronic Obstructive; Leukemia, Myeloid, Acute; Acute Lung Injury | Details |
| MyoCell SDF-1 | MyoCell SDF-1 | Clinical | U.S. Stem Cell | Heart Failure | Details |
